Which imaging modality is better for evaluating heart patients, PET or SPECT? After years of discussions and debates, the American Society of Nuclear Cardiology is now ready to point to PET as the No. 1 choice. “There are no clinical scenarios or patient subgroups where cardiac PET with myocardial blood flow should be excluded," the group wrote.

Current payment policies have health systems and physicians all over the country looking to learn more about these two business models. 

HighLife's new-look TMVR technology was designed to treat a wide range of patients. The two-part implant process includes a ring and a valve that centers itself inside that ring.

Most patients hospitalized for HFrEF are still not being prescribed quadruple medical therapy at discharge. Even those who are, researchers noted, still face a high risk of dying or returning to the hospital for heart failure-related symptoms. 

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.

Researchers see potential for this technology to make cardiac screening much easier for physicians who are not trained cardiologists.

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

The American Board of Cardiovascular Medicine is still pushing forward with its efforts to change how cardiologists are certified in the United States. While the group can reapply in the future for a standalone cardiology board, it is also looking at possible partnerships with other organizations.

The American Stroke Association's first major update in 7 years highlights the importance of coordinated care and expands patient access to critical treatments. It also includes the first detailed recommendations for treating stroke in pediatric patients.

More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed. 

This product was distributed throughout the United States from April 2022 to December 2025. Customers have been warned to stop taking it immediately. 

The ACC and AHA have published updated performance and quality measures focused on the diagnosis and management of peripheral artery disease. Several other specialty societies, including SCAI and SIR, also participated in the development of this new document.

How politically heated is the present moment? Enough to elicit verbal violence from trusted nurses. 

Movement during these exams can have downstream consequences such as diagnostic uncertainty, higher costs from repeat scans, and delayed clinical decision-making.